Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AB103 in Necrotizing Soft Tissue Infections
NCT01417780Phase 2Completed
- Sponsor
- Atox Bio
- Start
- Dec 2011
- Primary completion
- Sep 2012
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of reltecimod in necrotizing soft tissue infection (NSTI), sponsored by Atox Bio. Started Dec 2011; status: completed.
02
Drugs
reltecimod
03
Conditions
necrotizing soft tissue infection (NSTI)
Beyond the preview
Go deeper on NCT01417780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01417780.